Read More

PureTech Health Plc Provides Update On Progress Made Across Its Wholly Owned Programs And Founded Entities In 2022

Rapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone).

AKLI

Read More

Puretech Health Confirmed That It Has Exchanged Indicative, Non-binding Proposals With Nektar Therapeutics Regarding a Possible Combination

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") notes the recent press speculation and confirms that it has exchanged indicative, non-binding proposals with Nektar Therapeutics, Inc. ("Nektar") regarding a possible combination (which may include, amongst other things, an offer for share capital of PureTech) (the "Proposal").

NKTR